Acute Lymphoblastic Leukaemia (ALL)

Key Features of ALL:

• Acute means the disease develops quickly and can worsen rapidly if not treated.
• Lymphoblastic refers to the immature white blood cells, or lymphocytes, that are involved in the disease.
• Leukaemia refers to the cancer of the blood, where the abnormal white blood cells proliferate.

Types of ALL:

ALL is classified based on the specific type of lymphocyte affected:

• B-cell ALL: The most common type, which involves B lymphocytes (the cells that produce antibodies).
• T-cell ALL: Involves T lymphocytes, which play a role in immune responses.

Symptoms:

The rapid increase in immature white blood cells can cause a variety of symptoms due to the body’s inability to produce enough normal blood cells. Common symptoms include:

• Fatigue and weakness
• Pale skin
• Frequent infections
• Easy bruising or bleeding (due to low platelet counts)
• Bone pain or joint pain
• Swollen lymph nodes
• Fever
• Unexplained weight loss

Diagnosis:

ALL is typically diagnosed through:

• Blood tests: High levels of immature white blood cells (lymphoblasts) are usually found in the blood.
• Bone marrow biopsy: To examine the bone marrow for signs of leukaemia.
• Immunophenotyping: To determine the specific subtype of leukaemia and the type of abnormal cells.
• Genetic testing: To identify mutations that might influence treatment options.

Treatment:

ALL is an aggressive disease, but it is treatable, especially in children, who generally have better outcomes than adults. The standard treatment for ALL typically involves:

• Chemotherapy: The main treatment approach for ALL, aiming to kill the leukaemia cells or stop them from growing.
• Stem cell transplant (also called bone marrow transplant): In cases of relapse or high-risk disease, a transplant may be recommended.
• Immunotherapy: Uses the body’s immune system to target and kill leukaemia cells, and it has shown promising results in some cases of ALL.
• Targeted therapies: These aim at specific molecules or mutations that the leukaemia cells rely on for growth.

Prognosis:

The prognosis for ALL can vary based on factors such as age, the specific subtype of ALL, and how well the disease responds to treatment. In general:

• Children have a relatively high cure rate, with survival rates often exceeding 80-90%.
• Adults, particularly older adults, have a lower survival rate, though outcomes are improving with advances in treatment.

Overall, early diagnosis and treatment are critical to improving survival rates for individuals with ALL.